Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study.

PURPOSE To determine the incremental benefit of combined endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging, as compared with endorectal MR imaging alone, for sextant localization of peripheral zone (PZ) prostate cancer. MATERIALS AND METHODS This prospective multicenter study, conducted by the American College of Radiology Imaging Network (ACRIN) from February 2004 to June 2005, was institutional review board approved and HIPAA compliant. Research associates were required to follow consent guidelines approved by the Office for Human Research Protection and established by the institutional review boards. One hundred thirty-four patients with biopsy-proved prostate adenocarcinoma and scheduled to undergo radical prostatectomy were recruited at seven institutions. T1-weighted, T2-weighted, and spectroscopic MR sequences were performed at 1.5 T by using a pelvic phased-array coil in combination with an endorectal coil. Eight readers independently rated the likelihood of the presence of PZ cancer in each sextant by using a five-point scale-first on MR images alone and later on combined MR-MR spectroscopic images. Areas under the receiver operating characteristic curve (AUCs) were calculated with sextant as the unit of analysis. The presence or absence of cancer at centralized histopathologic evaluation of prostate specimens was the reference standard. Reader-specific receiver operating characteristic curves for values obtained with MR imaging alone and with combined MR imaging-MR spectroscopic imaging were developed. The AUCs were estimated by using Mann-Whitney statistics and appropriate 95% confidence intervals. RESULTS Complete data were available for 110 patients (mean age, 58 years; range, 45-72 years). MR imaging alone and combined MR imaging-MR spectroscopic imaging had similar accuracy in PZ cancer localization (AUC, 0.60 vs 0.58, respectively; P > .05). AUCs for individual readers were 0.57-0.63 for MR imaging alone and 0.54-0.61 for combined MR imaging-MR spectroscopic imaging. CONCLUSION In patients who undergo radical prostatectomy, the accuracy of combined 1.5-T endorectal MR imaging-MR spectroscopic imaging for sextant localization of PZ prostate cancer is equal to that of MR imaging alone.

[1]  N A Obuchowski,et al.  Sample size calculations in studies of test accuracy , 1998, Statistical methods in medical research.

[2]  Yuri Kitamura,et al.  Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. , 2006, AJR. American journal of roentgenology.

[3]  T. Stamey,et al.  Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.

[4]  J Alfred Witjes,et al.  Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. , 2005, Radiology.

[5]  J. Pauly,et al.  Dualband spectral‐spatial RF pulses for prostate MR spectroscopic imaging , 2001, Magnetic resonance in medicine.

[6]  P. Littrup,et al.  Workgroup #2: Screening and detection reference range/clinical issues of PSA , 1993, Cancer.

[7]  C. Öbek,et al.  Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. , 1999, The Journal of urology.

[8]  G. P. Krestin,et al.  Optimization of prostate carcinoma staging: Comparison of imaging and clinical methods , 1995 .

[9]  P. Carroll,et al.  Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. , 2004, Radiology.

[10]  J. Kurhanewicz,et al.  Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. , 2005, Radiology.

[11]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[12]  Benjamin M Yeh,et al.  Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. , 2008, Radiology.

[13]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[14]  T. Wheeler,et al.  Fresh tissue harvest for research from prostatectomy specimens , 1994, The Prostate.

[15]  Jean-Jacques Patard,et al.  Value of Ultrasound-Guided Systematic Sextant Biopsies in Prostate Tumor Mapping , 1999, European Urology.

[16]  N A Obuchowski,et al.  Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. , 1997, Statistics in medicine.

[17]  Silvia D. Chang,et al.  Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. , 2002, Radiology.

[18]  C. Gatsonis,et al.  Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. , 1990, The New England journal of medicine.

[19]  Ruth Etzioni,et al.  Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data , 2002, Medical care.

[20]  N A Obuchowski,et al.  Computing Sample Size for Receiver Operating Characteristic Studies , 1994, Investigative radiology.

[21]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[22]  C W Piccoli,et al.  Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. , 1994, Radiology.

[23]  M. Kattan,et al.  Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results. , 2003, Radiology.

[24]  P. Carroll,et al.  Focal therapy for prostate cancer 1996: maximizing outcome. , 1997, Urology.

[25]  N A Obuchowski,et al.  Multireader, multimodality receiver operating characteristic curve studies: hypothesis testing and sample size estimation using an analysis of variance approach with dependent observations. , 1995, Academic radiology.

[26]  Evis Sala,et al.  Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. , 2006, Radiology.

[27]  D. Mitchell,et al.  Early hepatocellular carcinoma that develops within macroregenerative nodules: growth rate depicted at serial MR imaging. , 1995, Radiology.

[28]  J A Smith,et al.  Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. , 1997, The Journal of urology.

[29]  J. Kurhanewicz,et al.  Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. , 2007, Radiology.

[30]  J Lipscomb,et al.  The burden of illness of cancer: economic cost and quality of life. , 2001, Annual review of public health.

[31]  Dennis W J Klomp,et al.  Initial Experience of 3 Tesla Endorectal Coil Magnetic Resonance Imaging and 1H-Spectroscopic Imaging of the Prostate , 2004, Investigative radiology.

[32]  P. Carroll,et al.  Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. , 1996, Radiology.

[33]  P. Carroll,et al.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. , 1999, Radiology.

[34]  D. Grignon,et al.  Prostate cancer: indicators of aggressiveness. , 1997, European urology.

[35]  C P Langlotz,et al.  Prostate cancer: what is the future role for imaging? , 2001, AJR. American journal of roentgenology.

[36]  A. D'Amico,et al.  Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. , 2000, The Journal of urology.

[37]  Alan W Partin,et al.  Radical prostatectomy for clinical stage T3a disease , 2007, Cancer.

[38]  R Alagappan,et al.  Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. , 1997, Radiology.

[39]  M. Cooperberg,et al.  National practice patterns and time trends in androgen ablation for localized prostate cancer. , 2003, Journal of the National Cancer Institute.

[40]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[41]  N A Obuchowski,et al.  Nonparametric analysis of clustered ROC curve data. , 1997, Biometrics.

[42]  J Kurhanewicz,et al.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 1999, Radiology.

[43]  J. Kurhanewicz,et al.  Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer , 2000, Magnetic resonance in medicine.

[44]  Silvia D. Chang,et al.  Combined diffusion‐weighted and dynamic contrast‐enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology , 2006, Journal of magnetic resonance imaging : JMRI.

[45]  P. Carroll,et al.  Prostate cancer: endorectal MR imaging and MR spectroscopic imaging--distinction of true-positive results from chance-detected lesions. , 2006, Radiology.